34 — Building High-Performance Type 1 Diabetes Care: Technology, Targets, and Equity (Dr Peter Adolfsson)

Suggest guests or get in contactHow do some countries consistently achieve lower HbA1c and better outcomes in type 1 diabetes while others struggle — even with the same technologies?In this episode, John Pemberton speaks with Dr Peter Adolfsson, paediatric diabetologist in Sweden and lead author of the ISPAD 2022 Exercise Guidelines, about what actually drives population-level improvements in type 1 diabetes care.Full show notes:https://theglucoseneverlies.com/episode-34-building-high-performance-type-1-diabetes-care-technology-targets-and-equity-dr-peter-adolfsson/KEY TOPICS• How Sweden’s national diabetes registry drives accountability and rapid improvement • Why structured onboarding and early follow-up are essential for CGM and AID success • The role of national collaboration between clinics to share best practice • Why the highest HbA1c group should often be first in line for AID systems • Moving toward time in tight range (3.9–7.8 mmol/L) as the next clinical target • Equity in diabetes technology: checking subconscious bias with real data • Why celebrating small improvements builds long-term engagementWHAT YOU’LL LEARN✓ Why early investment in education and follow-up changes long-term outcomes ✓ How national benchmarking between clinics improves diabetes care ✓ Why targets matter — changing what you measure changes what improves ✓ How to use AID systems strategically for people struggling with bolusing ✓ Why the first two years after diagnosis are a critical window for glycaemic outcomes ✓ The importance of psychology, social support, and multidisciplinary teamsFUTURE OF TYPE 1 DIABETES CARE• AI-supported platforms that analyse CGM data continuously • Clinics responding earlier when glucose control deteriorates • Personalised therapy combining insulin with adjunct treatments (e.g., GLP-1RA) • More flexible care models where stable patients may need fewer clinic visitsSupport GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.DisclaimerThis podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.The Glucose Never Lies® is independent by designWe do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:Buying the GNL a Coffee:https://www.buymeacoffee.com/jspfree2EnquiriesCollaboration: John Pemberton — [email protected]: Anjanee Kohli — [email protected] The Glucose Never Lies®Website: https://theglucoseneverlies.com/Instagram: https://www.instagram.com/theglucoseneverliesLinkedIn: https://www.linkedin.com/company/theglucoseneverliesLinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/X: https://twitter.com/GlucoseNLiesDisclaimer This content is for informational purposes only and does not constitute medical advice.© The Glucose Never Lies Ltd. All rights reserved.